Presence of Content Appealing to Youth on Cannabis-Infused Edibles Packaging

Abstract

Background

There is a lack of consistent regulation of cannabis edibles packaging to restrict youth-appealing content in the United States.

Objective

To describe content appealing to youth on U.S. cannabis-infused edibles packaging.

Methods

We analyzed 256 photos of cannabis-infused edibles packaging collected from U.S. adults from 25 states, District of Columbia, and Puerto Rico between May 2020 to August 2021. We coded the presence of product knockoffs, human and non-human creatures, images indicating flavor, text indicating flavor, and the number of colors. We compared these codes across states’ legalization status (medical and non-medical cannabis, medical cannabis only, or limited cannabis legalization).

Results

Overall, 15% of packages resembled product knockoffs, 23% contained human/non-human creatures, 35% contained flavor images, 91% contained flavor text, and median number of colors was 5 (range from 1 to 10+). Packages purchased in states with medical and non-medical cannabis, medical cannabis only, or limited cannabis legalization differed significantly on product knockoffs (11%, 26%, 38%, p = 0.007), human/non-human creatures (19%, 33%, 63%, p = 0.002), flavor text (93%, 81%, 100%, p = 0.046), and number of colors (median of 5, 5, and 10, p = 0.022).

Conclusions

Existing laws have not adequately limited content appealing to youth on U.S. cannabis-infused edibles packaging. Robust and consistent regulations in the U.S. are needed to ensure that the packaging of such products does not contain content that appeal to youth and lead to initiation or inadvertent ingestion.

Keywords:

• Cannabis-infused edibles
• packaging
• content appealing to youth

Disclosure statement

The authors report no conflict of interest.

Data availability statement

Data supporting the results or analyses are available upon request from the authors.

Additional information

Funding

This pilot study and Dr. Danielle Ompad were funded, in part, by the Center for Drug Use and HIV|HCV Research, a National Institute on Drug Abuse-funded P30 center (P30DA011041). Andy Tan is supported by the National Cancer Institute (R01CA237670) and National Institute on Drug Abuse (R21DA052421 and R01DA054236). The content is solely the responsibility of the authors and does not necessarily represent the official views of NIH.